Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts.
about
Antioxidant, antiglycation and cytotoxicity evaluation of selected medicinal plants of the Mascarene IslandsGlycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetesPrevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complicationLimited joint mobility syndrome in diabetes mellitus: A minireviewEdaravone protects against methylglyoxal-induced barrier damage in human brain endothelial cellsDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsProtein carbonylation, cellular dysfunction, and disease progressionDFT study of the mechanism of the reaction of aminoguanidine with methylglyoxalNew Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain.Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes?The hydrolyzable gallotannin, penta-O-galloyl-β-D-glucopyranoside, inhibits the formation of advanced glycation endproducts by protecting protein structure.Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages.Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay.Diabetic neuropathy: mechanisms to managementAminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice.Endotoxin mediated-iNOS induction causes insulin resistance via ONOO⁻ induced tyrosine nitration of IRS-1 in skeletal muscle.Effect of cranberry (Vaccinium macrocarpon) oligosaccharides on the formation of advanced glycation end-products.Ellagic acid, a new antiglycating agent: its inhibition of Nϵ-(carboxymethyl)lysine.Pathological aspects of lipid peroxidation.Carbonylation of myosin heavy chains in rat heart during diabetes.Diabetic nephropathy - complications and treatment.Combination of Medicinal Herbs KIOM-79 Reduces Advanced Glycation End Product Accumulation and the Expression of Inflammatory Factors in the Aorta of Zucker Diabetic Fatty Rats.Inhibition of advanced glycation end products by red grape skin extract and its antioxidant activity.Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products.KIOM-79, an Inhibitor of AGEs-Protein Cross-linking, Prevents Progression of Nephropathy in Zucker Diabetic Fatty Rats.Pomegranate phenolics inhibit formation of advanced glycation endproducts by scavenging reactive carbonyl species.Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study.Age-related vascular stiffening: causes and consequences.Inhibitory effect of gold nanoparticles on the D-ribose glycation of bovine serum albumin.Resorcylidene aminoguanidine (RAG) improves cardiac mitochondrial bioenergetics impaired by hyperglycaemia in a model of experimental diabetes.Inhibitory effect of Clitoria ternatea flower petal extract on fructose-induced protein glycation and oxidation-dependent damages to albumin in vitro.Systems biology of kidney diseases.New knowledge on the antiglycoxidative mechanism of chlorogenic acid.Dietary advanced glycation end products and aging.Preconditioning L6 Muscle Cells with Naringin Ameliorates Oxidative Stress and Increases Glucose Uptake.Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet.A global perspective of the genetic basis for carbonyl stress resistance.The production of cross-reactive autoantibodies that bind to bovine serum albumin in mice administered reducing sugars by subcutaneous injection.Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications.Low-molecular-weight chitosan scavenges methylglyoxal and N (ε)-(carboxyethyl)lysine, the major factors contributing to the pathogenesis of nephropathy.
P2860
Q21254685-E37CA039-E630-40EF-89A4-51975C1E7FE4Q24608214-C1CBFEE8-3BFB-4C09-B685-79BB736A77F8Q26751110-CC20CCED-673E-49D0-950D-42C01C838D64Q26798973-39D5CFA9-7FAA-46CD-B297-0E76C379B180Q27322912-5E0DD52A-0472-4F7E-AC08-80C097AB3959Q28086840-3B0A501E-58BC-49A5-A3CD-B6FA3FB3AF20Q28248107-9080DB9E-C222-419D-8C18-8EBBD5484BCDQ30013723-7498E23E-034D-4767-BAA6-85A28C13D4C5Q30235132-01762AA2-2D62-4912-9323-6B4679268312Q30352122-8CA7EE25-0EAA-43BD-9AD1-D3CB3DAA8CD3Q30372854-D8717887-AA1C-4258-823B-9D60F1BC3C6EQ30431517-F1E1644E-94D5-4C99-8ED5-4587E6D556BCQ33538479-4D58488A-9D9C-4C0F-B1FA-030D9C3EC200Q33554384-3E51DF04-557A-4055-A53A-E56466A1B94FQ33611742-86F466FE-49FF-4FD4-94BA-88B61435F071Q33785681-6425F3BF-79AC-4ACB-AF87-1C6E735B2E77Q33787882-56697AFA-BAA6-4389-93AB-8CFD84DBC0A6Q34068791-814983A8-E8A3-4B5B-BB69-F8830DD551D2Q34137628-6388AB55-AC4D-4808-A8F1-DA345823169EQ34334665-2442AEC0-BACB-4694-A79F-3FE7495D6664Q34387952-1E3F1D13-DBF2-44B9-93E9-690475CC5A5AQ34591116-FF145282-450B-49D1-A4EB-081210C527C5Q34816148-8DF134D5-FE15-4F85-8D73-851E46F8CA79Q34983879-8D756CEE-DBB9-4307-B826-71C640A56177Q35133347-0BD5C515-A010-413A-835A-ADD210EB03C1Q35261440-26C6710A-A9D7-4228-8787-7D951694009CQ35376455-B8C58F03-30CB-49CC-83EF-DB33506F1252Q35409645-625FC4F2-6499-48AB-A8BD-AEA2CAB9E6D8Q35487583-2272CD3A-899D-44C3-8BCA-1284E2648453Q35600193-712BFA24-8B2C-4D26-B7C0-44735ABD6A17Q35607690-AB3FA898-9345-4E3A-9176-922D96588A60Q35619034-E12D0632-7A51-47FB-9951-699113DF770CQ35650520-280468B8-BDD9-41D6-8A89-31BB4E94B262Q35670859-2019D262-69BB-4198-BDEF-735F39C16B52Q35683751-B5117DC5-6082-4EB1-B7D6-887D0ABEBE3BQ35684097-3134A314-4273-4826-9D40-F7FC36812FBDQ35746724-2CC041A6-9783-4FA4-B077-729EFA431F65Q35756294-C9BE358B-727B-4078-A0D9-336C42DAE498Q35766899-6BDDFCB5-D6AE-418B-AA7E-1D78784BE2B4Q35811824-22E6F2D1-D7CB-4CDE-AA02-709E6B8FAE6C
P2860
Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Use of aminoguanidine (Pimaged ...... dvanced glycation endproducts.
@ast
Use of aminoguanidine (Pimaged ...... dvanced glycation endproducts.
@en
type
label
Use of aminoguanidine (Pimaged ...... dvanced glycation endproducts.
@ast
Use of aminoguanidine (Pimaged ...... dvanced glycation endproducts.
@en
prefLabel
Use of aminoguanidine (Pimaged ...... dvanced glycation endproducts.
@ast
Use of aminoguanidine (Pimaged ...... dvanced glycation endproducts.
@en
P1476
Use of aminoguanidine (Pimaged ...... dvanced glycation endproducts.
@en
P356
10.1016/J.ABB.2003.08.013
P407
P577
2003-11-01T00:00:00Z